MedTrace Logo

Letrozole vs Danazol for Endometriosis-Related Pain: Randomized Trial

NCT07183787 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-19

No results posted yet for this study

Summary

Background:

Endometriosis is a chronic gynecological condition defined by the ectopic presence of endometrial glands and stroma outside the uterine cavity, most commonly diagnosed via laparoscopy. While its exact etiology remains uncertain, a positive family history is considered a significant risk factor. Danazol has historically demonstrated efficacy in alleviating endometriosis-related pain, while letrozole, primarily used in neoadjuvant settings, has recently emerged as a promising alternative. This study aimed to compare the mean reduction in pain scores between letrozole and danazol in women with laparoscopically confirmed endometriosis.

Objective:

To compare the efficacy of letrozole versus danazol in reducing pain scores among women diagnosed with endometriosis.

Material \& Methods:

Study Design: Randomized control trial Setting: Department of Obstetrics \& Gynaecology, Sharif Medical and Dental Hospital

Conditions

  • Endometriosis

Interventions

DRUG

Letrozole

Letrozole 2.5 mg orally once daily for 12 weeks.

DRUG

danazol

Danazol 200 mg orally twice daily for 12 weeks.

Sponsors & Collaborators

  • Sidra Salman

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2019-10-10
Completion
2025-07-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07183787 on ClinicalTrials.gov